Antihypertensive medications are one of the mainstays of treatment for a patient with CKD. Knowing the different classifications, indications, and adverse effects of the medication classes is a primary concern for the nephrology nurse. What is the impact of modality selection on medication choice and blood pressure management? What are the latest guidelines for care and evidence suggested in the management of hypertension for the individual with CKD? This workshop answers these questions.
Contact hours available until 4/24/2015
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure: Planning Committee: Kristin Larson – Consultant, Nephrology Clinical Solutions; Employee, Affymax; Other financial support, Kristin M. Larson, RN, MSN, LLC; Sandy Bodin – Employee, Affymax; Dawn Koonkongsatian – Employee, Fresenius Medical Care; Elizabeth St. John - Employee, Fresenius Medical Care
Presenter(s) have no disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declare.
Non-Endorsement of Products: Accreditation of activities for contact hours does not imply approval or endorsement of any product, advertising, or educational content by ANNA or the American Nurses Credentialing Center’s Commission on Accreditation.
Accreditation Statement: American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Objectives: • Discuss epidemiology and etiology of hypertension and explore assessment of blood pressure in patients with varying degrees of CKD. • Review mechanisms, dosing, common side effects, and drug interactions of medications used to treat hypertension in CKD. • Compare and contrast medications between and within drug classes to identify most appropriate agents for use in CKD and other comorbidities.